Warner Chilcott buys P&G Rx drugs division for $3.1 billion

Share this article:
Warner Chilcott will pay Procter & Gamble $3.1 billion for the consumer products giant's prescription drug division, including Actonel, for osteoporosis, and Asacol HD, for ulcerative colitis.

The deal gives Warner Chilcott, an Irish firm specializing in derm and women's health treatments, a small and aging but profitable portfolio of drugs that generated revenues of around $2.3 billion and net income of around $540 million for the year to June 30. Warner Chilcott also expands its presence in specialty markets and gets access to new physician offices in 14 countries. Most of the unit's 2,300 employees are expected to move to Warner Chilcott, tripling the size of the company's staff.

“Keeping the sales force focused is the most critical element of the plan,” said Warner Chilcott president and CEO Roger Boissonneault, who noted that in addition to expanding the company's US and European footprint, the deal adds gastroenterology to the firm's portfolio and bolsters its urology sales force ahead of its planned launch into the market for erectile dysfunction drugs.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...